Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
Ketamine Treatment Study for Adolescents and Young Adults with Obsessive-Compulsive Disorder (OCD)
Sponsor: NYPH YAC Youth Anxiety Center
Enrolling: Male and Female Patients
Study Length: 4 Months
Clinic Visits: 5
IRB Number: 7023
U.S. Govt. ID: NCT02422290
Contact: Kelsey Hill: 646-774-5793 /
Additional Study Information: The purpose of this study is to assess the effects of a single infusion of ketamine for adolescents and young adults with obsessive-compulsive disorder (OCD). Ketamine is a FDA-approved anesthetic medication that can possibly cause a rapid decrease in OCD symptoms. To be eligible to participate, patients need to have already tried at least one SRI medication and attempted a course of cognitive-behavioral therapy (CBT), unless unable to access or tolerate, with little or no change in OCD symptoms. The study involves: A screening visit, including a free, thorough diagnostic evaluation, in order to determine if the patient is eligible for the study; A one-time, low dose of intravenous ketamine administered at the Columbia University Medical Center; Phone check-ins and in-person visits for 2 weeks after the ketamine infusion; Three months of treatment for OCD including medication and/or cognitive-behavioral therapy at no cost.
This study is closed
Pablo Goldberg, M.D.
Do You Qualify?
Is the patient between the ages of 14 and 22? Yes No
Has the patient been diagnosed with OCD? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Kelsey Hill